What to Include in Your Tysabri Medical Records for PML Monitoring

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Specific Risks

If you are taking Tysabri, keeping organized medical records is crucial for monitoring the risk of progressive multifocal leukoencephalopathy (PML). The medical community has long recognized that early detection of PML improves outcomes, and a complete record of your treatment history, MRI results, and JC virus antibody status helps your healthcare team assess your individual risk. This page outlines the essential documents to include in your personal PML medical record checklist.

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Washington who have developed PML after Tysabri treatment, understanding the medical evidence and legal considerations—including the statute of limitations for filing a claim—is critical. The prescribing information for Tysabri includes a boxed warning stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning identifies three primary risk factors: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label further notes that "patients who are anti-JCV antibody positive have a higher risk for developing PML" and that "longer treatment duration, especially beyond 2 years" increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors are central to understanding the mechanistic pathway linking Tysabri to PML: the drug inhibits lymphocyte trafficking into the central nervous system, which can impair immune surveillance and allow JC virus reactivation.

Clinical Presentation and Diagnosis of PML

Clinically, PML presents with progressive neurological deficits such as weakness, visual changes, cognitive decline, and coordination problems. Diagnosis typically involves MRI imaging showing white matter lesions and detection of JC virus DNA in cerebrospinal fluid via PCR. The label emphasizes that healthcare professionals "should monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and that "TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, PML can still occur, and the outcome is often severe disability or death. From a risk perspective, the adequacy of warnings regarding Tysabri and PML is a key issue. The boxed warning and the TOUCH Prescribing Program—a restricted distribution system requiring patient enrollment and education—are designed to mitigate risk. The label states that "patients must be enrolled in the TOUCH Prescribing Program, read the Medication Guide, understand the risks associated with TYSABRI, and complete and sign the Patient Enrollment Form" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, questions may arise about whether healthcare providers adequately communicated these risks or whether patients fully understood the potential for PML, especially given the latency between exposure and documented harm.

Statute of Limitations for Tysabri Claims in Washington

The timeline between Tysabri initiation and PML onset can vary, with the label noting that herpes infections have been reported "from a few months to several years" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), and PML risk increases with longer treatment duration. For settlement-related considerations, affected patients in Washington must be aware of the statute of limitations, which generally governs the time window to file a lawsuit. In Washington, the statute of limitations for personal injury claims, including those related to pharmaceutical injuries, is typically three years from the date the injury was discovered or reasonably should have been discovered. For PML, this discovery date may be when symptoms first appeared or when a formal diagnosis was made. Given the progressive nature of PML and the potential for delayed diagnosis, patients should promptly seek legal counsel to evaluate their specific circumstances. Settlement amounts in Tysabri-related PML cases have historically varied based on factors such as severity of disability, medical expenses, lost wages, and the strength of evidence regarding inadequate warnings. In summary, the medical evidence clearly establishes that Tysabri increases PML risk, with identifiable risk factors and a need for vigilant monitoring. For Washington patients, the statute of limitations imposes a strict deadline for legal action, making timely consultation essential. The combination of clinical presentation, pharmacological mechanism, and risk factors provides a foundation for understanding both the medical and legal dimensions of Tysabri-associated PML.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri PML claims in Washington?

In Washington, the statute of limitations for personal injury claims, including those related to pharmaceutical injuries like Tysabri-associated PML, is typically three years from the date the injury was discovered or reasonably should have been discovered. For PML, this discovery date may be when symptoms first appeared or when a formal diagnosis was made. It is crucial to consult with an attorney promptly to ensure your claim is filed within the applicable deadline.

What are the risk factors for developing PML from Tysabri?

The prescribing information for Tysabri identifies three primary risk factors for PML: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk, and the risk increases with longer treatment duration.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Tysabri Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.